283 related articles for article (PubMed ID: 18413399)
21. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
22. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors.
Sudour H; Chastagner P; Claude L; Desandes E; Klein M; Carrie C; Bernier V
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):867-73. PubMed ID: 19632060
[TBL] [Abstract][Full Text] [Related]
23. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
24. Ovarian function after radioiodine therapy in patients with thyroid cancer.
Souza Rosário PW; Alvarenga Fagundes T; Villas-Boas Fagundes AS; Barroso AL; Lamego Rezende L; Lanza Padrão E; Guimarães VC; Horta AC; Franco M; Purisch S
Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):331-3. PubMed ID: 15977100
[TBL] [Abstract][Full Text] [Related]
25. Malformations in the offspring of women with thyroid cancer treated with radioiodine for the ablation of thyroid remnants.
do Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Purisch S
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):930-3. PubMed ID: 17160219
[TBL] [Abstract][Full Text] [Related]
26. [Offsprings of preconceptionally irradiated parents. Final report of a longitudinal study 1976-1994 and recommendations for patients' advisory].
Herrmann T; Thiede G; Trott KR; Voigtmann L
Strahlenther Onkol; 2004 Jan; 180(1):21-30. PubMed ID: 14704841
[TBL] [Abstract][Full Text] [Related]
27. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
28. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
29. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
[TBL] [Abstract][Full Text] [Related]
30. Thyroid cancer in infants and adolescents after Chernobyl.
Reiners C; Demidchik YE; Drozd VM; Biko J
Minerva Endocrinol; 2008 Dec; 33(4):381-95. PubMed ID: 18923372
[TBL] [Abstract][Full Text] [Related]
31. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer.
Vini L; Hyer S; Al-Saadi A; Pratt B; Harmer C
Postgrad Med J; 2002 Feb; 78(916):92-3. PubMed ID: 11807191
[TBL] [Abstract][Full Text] [Related]
32. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
33. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
34. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.
Seaberg RM; Eski S; Freeman JL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):355-9. PubMed ID: 19380356
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
36. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
37. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.
M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584
[TBL] [Abstract][Full Text] [Related]
38. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
[TBL] [Abstract][Full Text] [Related]
39. [Radiobiologic basis for using 131I to treat patients with thyroid cancer].
Suwiński R; Gawkowska-Suwińska M
Wiad Lek; 2001; 54 Suppl 1():266-77. PubMed ID: 12182035
[TBL] [Abstract][Full Text] [Related]
40. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
